Jupiter|Featured Event
Facebook Live: Sunharbo Approval for Secondary Stroke Prevention
Event Details
Facebook Live: Sunharbo Approval for Secondary Stroke Prevention
Presented by Jeff Gelblum, MD, FAAN
Thursday, November 19, 2026 • 12:30 PM ET
https://www.facebook.com/FCNeurology
What does a newly approved medication mean for people who have had a stroke or TIA? Join First Choice Neurology and Dr. Jeff Gelblum for a live discussion about Sunharbo (asundexian), a new option for reducing the risk of a future stroke in certain adults.
The FDA approved Sunharbo last week for use alongside antiplatelet medication in adults who recently had a mild-to-moderate stroke caused by a clot that did not come from the heart, or a high-risk transient ischemic attack (TIA). 𝗦𝘂𝗻𝗵𝗮𝗿𝗯𝗼 𝗶𝘀 𝘁𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝗙𝗗𝗔-𝗮𝗽𝗽𝗿𝗼𝘃𝗲𝗱 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝘁𝗼 𝗯𝗹𝗼𝗰𝗸 𝗳𝗮𝗰𝘁𝗼𝗿 𝗫𝗜𝗮, a protein involved in blood clotting.
Dr. Gelblum will discuss:
𝗪𝗵𝗼 𝗺𝗮𝘆 𝗯𝗲 𝗲𝗹𝗶𝗴𝗶𝗯𝗹𝗲. He’ll explain which types of stroke and why stroke prevention in people with atrial fibrillation is outside this approval.
𝗪𝗵𝗮𝘁 𝘁𝗵𝗲 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹 𝗳𝗼𝘂𝗻𝗱. In a recent study, adding Sunharbo lowered the relative risk of an ischemic stroke.
𝗪𝗵𝗲𝗻 𝘁𝗵𝗲 𝗺𝗲𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗺𝗮𝘆 𝗯𝗲 𝗮𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲. Bayer expects shipping to begin shortly. Local availability may vary.